Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

Exclusion Criteria

• •1. The target disease has cerebral metastasis;
• •2. medical history and complications
• •* patients had uncontrolled serious medical condition that the investigator considered may affect the subject's to receive treatment under the study program, For example, patients with severe medical diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, active peptic ulcer, etc.
• •* Dementia, changing of mental state or any mental illness which could hinder understanding or informed consent or fill out questionnaires;
• •* History of allergy or hypersensitivity to any therapeutic ingredient;
• •* Combined with other malignant tumors excepted pancreatic cancer within the first 5 years of randomization, excepted well-treated basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical resection, and ductal carcinoma in situ of the breast after radical resection.
• •* Previously received systemic therapy for advanced/metastatic pancreatic cancer;
• •* Subjects who had previously been pathologically diagnosed with squamous cell carcinoma (no organ limitation) and received neoadjuvant/adjuvant therapy with taxa regimen.
• •* Patients who had Grade 2 or above Peripheral neuropathy.
• •3. Abnormal results of physical examination and laboratory examination
• •* Absolute neutrophil count (ANC) 90g/L 1.5 × 109/L; Platelets (PLT) 90g/L 100 × 109/L; Hemoglobin (Hgb) \< 90g/L
• •* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]/ alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase \[SGPT\]) \>2.5 × institutional upper limit of normal (ULN), \>5 × institutional upper limit of normal (ULN) (hepatic metastases); Total bilirubin (TBIL)\>1.5 × ULN;
• •* Creatinine (CRE)\> 1.5 × ULN
• •* Prothrombin time (PT) and international normalized ratio (INR) \> 1.5 × ULN. Unless the subject had received anticoagulant treatment
• •4. Subjects had hepatitis b surface antigen (HBsAg)-positive and hbv-dna titer in peripheral blood greater than or equal to 1000 copy number /L;If HBsAg is positive and the peripheral blood hbv-dna \<1000 copy number /L, the subjects will be eligible for inclusion if the investigator considers that chronic hepatitis b is stable and does not increase the risk of subjects.
• •5. Human immunodeficiency virus (HIV)- or hepatitis C virus (HCV) positive patients;
• •6. Patients combined with other anti-tumor drugs.
• •7. Participation in any trial drug treatment or another interventional clinical trial 30 days before screening period.
• •8. The researchers considered that there were other conditions that were not suitable for enrollment.